Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis (CP3)

Brief description of study

The goal of this research is to test a novel centralized care coordinator program to assist patients with psoriatic disease in lowering their risk of cardiovascular disease through the application of standard of care approaches to improving modifiable cardiovascular risk factors.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Psoriasis, Psoriatic disease, Psoriatic Arthritis
Age: Between 40 Years - 75 Years
Gender: All

Inclusion

Willing and able to provide informed consent
Male or female aged 40-75
Being seen by a dermatologist in routine care for the primary encounter of psoriasis

Exclusion

Currently taking a prescription lipid lowering medication such as statins, PCSK9 inhibitors, bempedoic acid, or ezetimibe
Pregnant or planning pregnancy in the next 6 months
Known history of cardiovascular disease

Updated on 09 Mar 2024. Study ID: 853218

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).